Gitanjali Jain - Kezar Life Senior Affairs
| KZR Stock | USD 7.54 0.08 1.05% |
Executive
Gitanjali Jain is Senior Affairs of Kezar Life Sciences
| Address | 4000 Shoreline Court, South San Francisco, CA, United States, 94080 |
| Phone | 650 822 5600 |
| Web | https://www.kezarlifesciences.com |
Kezar Life Management Efficiency
The company has Return on Asset of (0.2807) % which means that on every $100 spent on assets, it lost $0.2807. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.5148) %, meaning that it generated no profit with money invested by stockholders. Kezar Life's management efficiency ratios could be used to measure how well Kezar Life manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/22/2024, Return On Tangible Assets is likely to drop to -0.48. In addition to that, Return On Capital Employed is likely to drop to -0.54. At this time, Kezar Life's Net Tangible Assets are relatively stable compared to the past year. As of 11/22/2024, Non Currrent Assets Other is likely to grow to about 5.9 M, while Non Current Assets Total are likely to drop slightly above 7.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Paul Reider | Coherus BioSciences | 54 | |
| Jeff Cole | Cadrenal Therapeutics, Common | N/A | |
| Mark Conley | SAB Biotherapeutics | N/A | |
| Jami Taylor | Coherus BioSciences | N/A | |
| Robert MD | Lyra Therapeutics | N/A | |
| Mark Winderlich | Hookipa Pharma | 38 | |
| Robert Richard | Lyra Therapeutics | 66 | |
| Ronan JD | Lyra Therapeutics | 51 | |
| Michael Szumera | Hookipa Pharma | N/A | |
| Ellen Cavaleri | Lyra Therapeutics | N/A | |
| Vineeta Belanger | Lyra Therapeutics | N/A | |
| Theresa Lavallee | Coherus BioSciences | 58 | |
| Cheston Turbyfill | Coherus BioSciences | N/A | |
| Michael Chen | Coherus BioSciences | N/A | |
| Gloria Cosgrove | Lyra Therapeutics | N/A | |
| MRCP MD | Coherus BioSciences | 55 | |
| Scott Saywell | Coherus BioSciences | N/A | |
| Allison Nance | Lyra Therapeutics | N/A | |
| John Bishop | Lyra Therapeutics | 62 | |
| MD MBA | SAB Biotherapeutics | 51 | |
| Carlos Carillo | SAB Biotherapeutics | N/A | |
Management Performance
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.28 |
Kezar Life Sciences Leadership Team
Elected by the shareholders, the Kezar Life's board of directors comprises two types of representatives: Kezar Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kezar. The board's role is to monitor Kezar Life's management team and ensure that shareholders' interests are well served. Kezar Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kezar Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joe Tedrick, Vice Resources | ||
| Christopher Kirk, Co-Founder, Chief Scientific Officer | ||
| Marc Belsky, CFO, Secretary | ||
| Noreen MD, Chief Officer | ||
| John Fowler, CoFounder Director | ||
| Pattie Chiang, Senior Controller | ||
| Michael Wolfe, Sr Operations | ||
| Jack Taunton, Co-Founder | ||
| Neel Anand, Senior Discovery | ||
| Zung To, Senior Development | ||
| Gitanjali Jain, Senior Affairs | ||
| PharmD Mordwinkin, Chief Strategy | ||
| Mark Schiller, Chief Officer |
Kezar Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kezar Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (14.22) % | ||||
| Current Valuation | (76.83 M) | ||||
| Shares Outstanding | 7.3 M | ||||
| Shares Owned By Insiders | 14.79 % | ||||
| Shares Owned By Institutions | 63.90 % | ||||
| Number Of Shares Shorted | 177.96 K | ||||
| Price To Earning | (9.34) X | ||||
| Price To Book | 0.41 X |
Pair Trading with Kezar Life
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kezar Life position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kezar Life will appreciate offsetting losses from the drop in the long position's value.Moving against Kezar Stock
| 0.7 | NKTX | Nkarta Inc | PairCorr |
| 0.63 | CYRX | Cryoport | PairCorr |
| 0.58 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.57 | VALN | Valneva SE ADR | PairCorr |
| 0.53 | BACK | IMAC Holdings | PairCorr |
The ability to find closely correlated positions to Kezar Life could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kezar Life when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kezar Life - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kezar Life Sciences to buy it.
The correlation of Kezar Life is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kezar Life moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kezar Life Sciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kezar Life can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Kezar Stock Analysis
When running Kezar Life's price analysis, check to measure Kezar Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kezar Life is operating at the current time. Most of Kezar Life's value examination focuses on studying past and present price action to predict the probability of Kezar Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kezar Life's price. Additionally, you may evaluate how the addition of Kezar Life to your portfolios can decrease your overall portfolio volatility.